Post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when comparing active treatment and sham eyes to their corresponding contralateral eyes across multiple endpoints – Company plans to discuss findings with regulators in Q3
… transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced … webcast will be available for approximately 30 days. About Axiomer ® ProQR is pioneering a next-generation RNA base …
… it will present preclinical data for its proprietary Axiomer™ RNA editing technology platform and its AX-0810 … a next-generation RNA base editing technology called Axiomer™, which could potentially yield a new class of …
… transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced the … has served on ProQR’s Supervisory Board since 2014. About Axiomer ® ProQR is pioneering a next-generation RNA base …
… transformative RNA therapies based on its proprietary Axiomer ™ RNA editing technology platform today announced … will then be available for approximately 30 days. About Axiomer ™ ProQR is pioneering a next-generation RNA base editing technology called Axiomer ™ , which could potentially yield a new class of …
… ophthalmic programs supports ProQR’s strategic focus on Axiomer® RNA editing platform technology and continued … transformative RNA therapies based on its proprietary Axiomer ® RNA editing technology platform, today reported its …
… trial in 2022. RNA base-editing platform technologies – Axiomer ® and Trident ® ProQR has been further optimizing the Axiomer ® Editing Oligonucleotide (EON) designs and shown … will develop selected genetic eye disease targets with Axiomer ® , and will provide further guidance on this in H2 …